Capricor Therapeutics Ownership
| CAPR Stock | USD 19.06 0.24 1.28% |
Shares in Circulation | First Issued 2001-03-31 | Previous Quarter 31.8 M | Current Value 33.1 M | Avarage Shares Outstanding 5.4 M | Quarterly Volatility 9.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Capricor |
Capricor Stock Ownership Analysis
About 17.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.03. Capricor Therapeutics last dividend was issued on the 5th of June 2019. The entity had 1:10 split on the 5th of June 2019. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. The company was founded in 2005 and is headquartered in San Diego, California. Capricor Therap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 48 people. For more info on Capricor Therapeutics please contact the company at 858 727 1755 or go to https://www.capricor.com.Besides selling stocks to institutional investors, Capricor Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Capricor Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Capricor Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Capricor Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Capricor Therapeutics Insider Trades History
About 17.0% of Capricor Therapeutics are currently held by insiders. Unlike Capricor Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Capricor Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Capricor Therapeutics' insider trades
Capricor Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Capricor Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Capricor Therapeutics backward and forwards among themselves. Capricor Therapeutics' institutional investor refers to the entity that pools money to purchase Capricor Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 158.4 K | Partner Fund Management Lp | 2024-09-30 | 152.8 K | Ghost Tree Capital, Llc | 2024-09-30 | 125 K | Stempoint Capital Lp | 2024-09-30 | 93.6 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 90.4 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 89.3 K | Boothbay Fund Management, Llc | 2024-09-30 | 87.8 K | Ubs O'connor Llc | 2024-09-30 | 82.9 K | Goldman Sachs Group Inc | 2024-06-30 | 82.7 K | Blackrock Inc | 2024-06-30 | 1.6 M | Vanguard Group Inc | 2024-09-30 | 1.6 M |
Capricor Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Capricor Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Capricor Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Capricor Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Capricor Therapeutics Outstanding Bonds
Capricor Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Capricor Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Capricor bonds can be classified according to their maturity, which is the date when Capricor Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Capricor Therapeutics Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pair Trading with Capricor Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Capricor Stock
| 0.86 | NKTX | Nkarta Inc | PairCorr |
| 0.79 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.75 | CYRX | Cryoport | PairCorr |
| 0.73 | VALN | Valneva SE ADR | PairCorr |
| 0.72 | MTEM | Molecular Templates | PairCorr |
The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.
The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.